These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21479595)

  • 21. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy.
    Al-Shali K; Cao H; Knoers N; Hermus AR; Tack CJ; Hegele RA
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5655-60. PubMed ID: 15531525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
    Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of familial partial lipodystrophy caused by a novel lamin A/C (LMNA) mutation in exon 1 (D47N).
    Kutbay NO; Yurekli BS; Onay H; Altay CT; Atik T; Hekimsoy Z; Saygili F; Akinci B
    Eur J Intern Med; 2016 Apr; 29():37-9. PubMed ID: 26775134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
    Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
    Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.
    Imachi H; Murao K; Ohtsuka S; Fujiwara M; Muraoka T; Hosokawa H; Ishida T
    Endocrine; 2009 Feb; 35(1):18-21. PubMed ID: 19011997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study.
    Guidorizzi NR; Valerio CM; Viola LF; Veras VR; Fernandes VO; Lima GEDCP; Flor AC; Araújo JS; Gonçalves Muniz RB; Moreira RO; De Paula FJA; Zajdenverg L; Dantas JR; Godoy-Matos AF; Montenegro Júnior RM; Foss-Freitas MC
    Front Endocrinol (Lausanne); 2024; 15():1359211. PubMed ID: 38887266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
    Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
    Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
    Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
    Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A complex case of diabetes due to LMNA mutation].
    Ambonville C; Bouldouyre MA; Laforêt P; Richard P; Benveniste O; Vigouroux C
    Rev Med Interne; 2017 Oct; 38(10):695-699. PubMed ID: 28545855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants.
    Broekema MF; Savage DB; Monajemi H; Kalkhoven E
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 May; 1864(5):715-732. PubMed ID: 30742913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.
    Chen X; Ma Z; Chen P; Song X; Li W; Yu X; Xie J
    Front Endocrinol (Lausanne); 2022; 13():830708. PubMed ID: 35422762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl.
    Krawiec P; Mełges B; Pac-Kożuchowska E; Mroczkowska-Juchkiewicz A; Czerska K
    BMC Pediatr; 2016 Mar; 16():38. PubMed ID: 26976018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
    Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
    Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations.
    Subramanyam L; Simha V; Garg A
    Clin Genet; 2010 Jul; 78(1):66-73. PubMed ID: 20041886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biochemical, hormonal and genetic evaluation of the families of two Brazilian patients with type 2 familial partial lipodystrophy].
    Caldas D; Silva Júnior WS; Simonetti JP; Costa EV; Farias ML
    Arq Bras Endocrinol Metabol; 2013 Nov; 57(8):583-93. PubMed ID: 24343626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial Partial Lipodystrophy: Clinical Features, Genetics and Treatment in a Greek Referral Center.
    Kountouri A; Korakas E; Maratou E; Ikonomidis I; Balampanis K; Liatis S; Tentolouris N; Toulas P; Kousathana F; Giatzakis C; Dimitriadis GD; Lambadiari V
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipodystrophy: an unusual diagnosis in a case of oligomenorrhea and hirsutism.
    Keller J; Subramanyam L; Simha V; Gustofson R; Minjarez D; Garg A
    Obstet Gynecol; 2009 Aug; 114(2 Pt 2):427-431. PubMed ID: 19622949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
    Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
    Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.